Products for Research Use Only
RegisterLogin

Bortezomib (GMP)

CAT: 0804-HY-10227GSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10227GSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Bortezomib (GMP) (PS-341 (GMP) ) is Bortezomib produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM)[2]. Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) [7].
Product Name Alternative
PS-341 (GMP) ; LDP-341 (GMP) ; NSC 681239 (GMP)
UNSPSC
12352005
Target
Apoptosis; Autophagy; NF-κB; Proteasome; TREM receptor
Related Pathways
Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Field of Research
Cancer
Smiles
OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
Molecular Formula
C19H25BN4O4
Molecular Weight
384.24
References & Citations
[1]Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59 (11) :2615-22.|[2]Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1 (7) :913-24. |[3]Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107 (1) :257-64.|[4]Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3 (2) :333-9. |[5]Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011 Dec;12 (67) :471-80. |[6]Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem. 2006 Jan 13;281 (2) :1107-18. |[7]Wang Y, et al. TREM2-Mediated Cholesterol Efflux in Macrophages Inhibits Anti-Tumor Immunity via Limitation of CD4+ T and NK Cells. Adv Sci (Weinh) . 2025 Oct 20:e06995.
Shipping Conditions
Room temperature
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10227-01Bortezomib
HY-W048404-01Bortezomib impurity A
HY-10227R-01Bortezomib (Standard)
HY-169144Bortezomib analog
HY-10227S-01Bortezomib-d8
HY-125939-01Bortezomib-pinanediol
HY-135396-01(1S,2S) -Bortezomib
HY-Z4561S-01Bortezomib trimer-d15
HY-W048407Bortezomib impurity 12
HY-169158Bortezomib analog 1

Alternative Products

CatalogName
RM-B201439-01Bortezomib

Popular Products